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Introduction:  Ameloblastoma  is a rare,  benign,  purely  epithelial  odontogenic  tumour,  characterized  by  a
high  potential  for local  invasion  and  recurrence.
Objective:  To study  the  epidemiological  and histological  characteristics  of  ameloblastoma.  To  study  Ki67
and  CD10  immunostaining  in  ameloblastoma  and  to  investigate  a  possible  correlation  between  these  two
markers  and  recurrence  of  this  tumour.
Methods:  An immunohistochemical  study  using  Ki67 and  CD10  monoclonal  antibodies  was  performed
on  37  parafﬁn  blocks  obtained  from  the  Charles-Nicolle  hospital  pathology  department  in Tunis  over  a
9-year  period  (2004–2012).  Statistical  analysis  was  performed  with  Statistical  Package  for  Social  Sciences
(SPSS)  software  version  15.1.
Results:  This  series  of  37  cases  comprised  21  males  and  16  females  (sex  ratio:  1.3) with  a mean  age  of 39
years  (range:  7  to 70 years),  corresponding  to  36  cases  of  intraosseous  ameloblastoma  and  one  case  of
gingival  ameloblastoma.  Thirty-two  cases  were  polycystic  and  5  cases  were  unicystic.  Eighteen  cases  of
local recurrence  were  observed.  No  correlation  was  demonstrated  between  recurrence  and  the  various
clinical  and  histological  parameters  and  treatment  modalities.  However,  a signiﬁcant  correlation  was
demonstrated  between  recurrence  and  Ki67  and  CD10  expression  (P = 0.000  and 0.002,  respectively).
Conclusion:  The  Ki67  proliferation  index  and  stromal  CD10  expression  can  be considered  to be predictive
factors  of ameloblastoma  recurrence.. Introduction
Ameloblastoma is the most common odontogenic tumour, rep-
esenting about 1% of all tumours of the oral cavity [1]. This tumour
rises from epithelial cell rests of Malassez after regression of the
namel organ. It affects the mandible and the maxilla in 80% and
0% of cases, respectively [2].
According to the latest WHO  classiﬁcation, ameloblastoma is
ubdivided into intraosseous (central) ameloblastoma and tissue
peripheral) ameloblastoma with various architectural variants [3].
It is a locally invasive tumour with a high tendency to recur-
ence [4] and even metastasis in rare cases [5]. This invasive nature
f ameloblastoma has consequences for treatment, ranging from
imple tumour resection to wide or even radical resection.
Recent studies have suggested that Ki67 and CD10 expression in
umour tissue may  be associated with a more invasive proﬁle and a
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higher risk of recurrence of certain tumours, including ameloblas-
toma [6,7].
The objectives of this study were to:
• identify the epidemiological and histological characteristics of
ameloblastoma;
• study the immunohistochemical expression of Ki67 and CD10 in
ameloblastoma, and investigate a possible correlation between
these two markers and the recurrence rate of this tumour.
2. Material and methods
This retrospective study was based on a series of 37 cases of
ameloblastoma collected in the Charles-Nicolle hospital pathology
department in Tunis over a 9-year period (2004–2012).
The objectives of this study were to identify the epidemiolog-
ical and histological characteristics of ameloblastoma, study the
immunohistochemical expression of Ki67 and CD10 in this tumour,
and investigate a possible correlation between these two markers
and the ameloblastoma recurrence rate.
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Fig. 1. Ki67-positive tumour cells with a Ki67 index of 14% (× 200). Arrow indicating
labelled cells.
Table 1
Ki67 expression according to the histological characteristics of ameloblastomas.
Intensity of Ki67 labelling
Weak (%) Moderate (%) Intense (%)
Site
Mandibular 11 (32) 14 (42) 9 (26)
Maxillary 1 (33) 1 (33) 1 (33)
Size
≤  4 cm 6 (26) 10 (44) 7 (30)
>  4 cm 5 (36) 8 (57) 1 (7)
Histological type
Polycystic 8 (25) 17 (53) 7 (22)
Unicystic 3 (60) 1 (20) 1 (20)
Architectural variant76 B. Ahlem et al. / European Annals of Otorhinolary
Epidemiological and clinical data and outcome were collected by
etrospective review of the patients’ medical charts in the depart-
ent of maxillofacial surgery of the same hospital. Histological
lides were reviewed and tumours were classiﬁed according to the
HO  2005 classiﬁcation [3].
Slides comprising the largest amount of tumour tissue and not
ontaining any bone fragments were selected in each case and the
orresponding blocks were retrieved.
The three-layer immunoperoxidase staining protocol was  used,
omprising a LEICA kit (NovoLink) with revelation by DAB
diaminobenzidine) chromogen.
Ki67 immunolabelling has an exclusively nuclear distribution
ith brownish staining and tumour cells presenting total nuclear,
ocal nuclear or nucleolar labelling are considered to be positive.
Ki67 immunolabelling was considered to be:
low: 0 to 7% of tumour cells are labelled;
moderate: 8 to 15% of tumour cells are labelled;
intense: > 15% of tumour cells are labelled.
CD10 immunolabelling was evaluated by the score proposed by
gawa et al. [8]: cytoplasmic immunolabelling was initially evalu-
ted according to the following score:
0: no labelling;
1: weak cytoplasmic labelling;
2: moderate cytoplasmic labelling;
3: intense cytoplasmic labelling.
CD10 immunolabelling was then evaluated according to a semi-
uantitative score:
0: < 10% of cells are labelled;
1: 10 to 25% of cells are labelled;
2: 25 to 50% of cells are labelled;
3: > 50% of cells are labelled.
After combining the immunolabelling intensity scores and the
ercentage of immunolabelled cells, immunolabelling was  consid-
red to be:
negative: score 0–1;
+: score 2;
++: score 3;
+++: score 4–5.
Statistical analysis was performed with Statistical Package for
ocial Sciences (SPSS) software version 15.1. A descriptive and ana-
ytical study of the series was performed.
. Results
This series comprised 21 males (56.8%) and 16 females (43.2%)
ith a sex ratio of 1.3 and a mean age of 39 years (range: 7 to 70
ears). The tumour involved the mandible in 34 cases (94%) and
he maxilla in 3 cases (6%). The long axis of the tumours ranged
etween 1 and 15 cm with a mean of 4 cm.  This series comprised
6 cases of intraosseous ameloblastoma (97%) and one case of
xtraosseous gingival ameloblastoma (3%). Thirty-two cases were
olycystic/solid (86%) and 5 cases were unicystic (14%), including 4
ases corresponding to a mural subtype and 1 case corresponding
o a luminal subtype.
The corresponding architectural variant was speciﬁed for each
f the various types of ameloblastoma.Follicular 7 (39) 7 (39) 4 (22)
Plexiform 3 (30) 4 (40) 3 (30)
Other 2 (22.1) 4 (44.5) 3 (33.4)
4. Ki67 expression
In our study, the Ki67 proliferation index varied between 2% and
22% with a mean of 10.5% (Fig. 1) (Table 1). Ki67 immunolabelling
was weak in 12 cases (30%), moderate in 15 cases (49%), and intense
in 10 cases (21%).
Comparison of Ki67 expression with tumour site, tumour size,
architectural variants and histological types did not reveal any sta-
tistically signiﬁcant differences. However, immunolabelling was
moderate and intense in the follicular variant.
5. CD10 expression by stromal cells
Immunolabelling was negative in 9 cases (24%), weakly posi-
tive in 10 cases (27%), moderately positive in 15 cases (41%) and
intensely positive in 3 cases (8%) (Fig. 2) (Table 2).
No statistically signiﬁcant correlation was observed between
stromal CD10 expression and tumour site, tumour size, histological
type and the various architectural variants.
6. Treatment modalities
All patients were treated surgically. Thirty-two patients (86%)
were treated conservatively and 5 other patients (14%) underwent
ﬁrst-line radical surgery.7. Outcome and recurrence
Mean follow-up was  79 months (range: 2 to 300 months)
(Table 3). Two patients were lost to follow-up after one month.
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Table  2
CD10 expression by stromal cells according to the histological characteristics of ameloblastomas.
CD10 labelling of stromal cells
Negative (%) Low (%) Moderate (%) Intense (%)
Site
Mandibular 8 (23.5) 8 (23.5) 15 (44) 3 (9)
Maxillary 1 (33.3) 2 (33) – –
Size
≤  4 cm 3 (13) 6 (26) 12 (53) 2 (9)
>  4 cm 4 (28.6) 5 (36) 4 (28.6) 1 (7)
Histological type
Polycystic 6 (20) 9 (31) 14 (48.2) 3 (10.7)
Unicystic 1 (20) 2 (40) 2 (40) –
Architectural variant
Follicular 5 (28)
Plexiform 4 (40) 
Other  0 
Fig. 2. Moderately positive CD10 immunolabelling of stromal cells (CD10 × 200).
Arrow indicating labelled cells.
Table 3
Relationship between recurrence and various parameters predictive of recurrence.
Predictive
parameters
Groups Number of
recurrent cases
P-value
Age (years) ≤ 35
> 35
10
8
0.618
Gender Male
Female
11
7
0.603
Tumour site Mandible
Maxilla
17
1
0.912
Tumour size (cm) ≤ 4
> 4
13
5
0.219
Histological type Polycystic
Unicystic
17
1
0.168
Architectural
variant
Follicular
Plexiform
Mixed
Acanthomatous
granular cell
8
3
2
5
0
0.087
Therapeutic
modalities
Conservative
surgery
Radical surgery
16
2
0.677
Expression of the
Ki67
Weak
Moderate
2
8
8
0.000
Expression of the Negative 3 0.002
A
p
1
6CD10 Weak
Moderate
Intense
1
11
3
 favourable outcome was observed in 19 patients (51%) and 18
atients (49%) experienced recurrence, with a single recurrence in
1 cases and multiple recurrences in 7 cases.
The 6-month and 5-year overall recurrence-free survivals were
1% and 45%, respectively.6 (33.3) 6 (33.3) 1 (5.5)
3 (30) 2 (20) 1 (10)
1 (11.1) 7 (77.8) 1 (11.1)
Parameters predictive of recurrence were clinical (age, gender,
tumour site, tumour size), histological (architectural variant, his-
tological type), immunohistochemical (Ki67 and CD10 expression)
and treatment modalities. No signiﬁcant correlation was  observed
between recurrence and clinical parameters or recurrence and his-
tological parameters.
A statistically signiﬁcant correlation was  demonstrated
between recurrence and Ki67 expression (P = 0.000) and between
recurrence and CD10 expression (P = 0.002).
8. Discussion
Ameloblastoma is a rare tumour, representing only 1% of all
tumours of the oral cavity [1] and about 11% of all odontogenic
tumours [9,10]. This tumour is usually observed in young adults, but
can occur at any age with a mean of age of onset of 40 years [11,12],
with no sex predilection [13,14]. The mean age of the patients in
the present study was 39 years with a slight male predominance
(sex ratio = 1.3).
In line with published series that have reported a predominantly
mandibular site of ameloblastoma (80 to 99% of cases) [14,15], and
more rarely a maxillary site (3 to 20% of cases) [15,16], a mandibular
site was observed in 92% of cases and a maxillary site was observed
in 8% of cases in our series.
Tumour diameter generally ranges between 3 and 24 cm with a
mean of 4.3 cm [17]. In our study, the mean tumour diameter was
4 cm with a range from 1 to 15 cm.
According to the 2005 WHO  classiﬁcation [3], ameloblastoma is
subdivided according to its site as intraosseous (central) ameloblas-
toma and extraosseous (tissue or peripheral) ameloblastoma. Our
series was  composed of 36 cases (97%) of intraosseous ameloblas-
toma and one case (3%) of gingival ameloblastoma.
Three histological types have been identiﬁed: solid/polycystic,
unicystic and desmoplastic ameloblastoma. Several architectural
variants have also been identiﬁed: follicular, plexiform, acan-
thomatous, granular cell and mixed. Follicular and plexiform
varieties are the most widespread with respective frequencies of
34 and 30%, while the acanthomatous variety is less frequent (11%)
[18]. The distribution of architectural variants in our series was con-
cordant with the data of the literature, showing a predominance
of the follicular variant (45%), followed by the plexiform variety
(26%), while the acanthomatous variety represented only 16% of
cases.
Treatment is surgical and is primarily designed to ensure
recurrence-free tumour resection with acceptable cosmetic and
functional results. Surgical enucleation was the preferred tech-
nique in our study (86.5%), but ﬁrst-line radical surgery was
performed in 13.5% of cases.
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Ameloblastoma is a locally invasive tumour, causing bone
estruction and soft tissue invasion [18]. It is also characterized by
 very high recurrence rate, even following complete resection with
egative surgical margins [3,4]. More than 50% of patients relapse
uring the ﬁrst ﬁve postoperative years [12] and the 5-year recur-
ence rate ranges between 9 and 65%. The 5-year recurrence rate
as 49% in our series.
Age and gender were not considered to be predictive factors
f tumour recurrence according to published studies [19], as con-
rmed by the present study.
Mandibular ameloblastomas are associated with a higher recur-
ence rate than maxillary ameloblastomas [20]. In our series,
4% of recurrences concerned mandibular tumours, while 6% of
ecurrences concerned maxillary tumours, but with no signiﬁcant
ifference between the two groups (P = 0.912).
No signiﬁcant correlation between recurrence and tumour size
P = 0.375) was observed by AbdelAziz and Amin [17], who  also
eported a higher recurrence rate (60%) for ameloblastomas larger
han 4 cm in diameter. However, in our study, 72% of recurrent
umours were less than or equal to 4 cm in diameter, while only 28%
f tumours were larger than 4 cm,  but with no signiﬁcant difference
etween the two groups (P = 0.219).
Certain histological characteristics are also predictive of the
meloblastoma recurrence rate. Some of these characteristics have
lready been validated, while others have been proposed more
ecently, such as Ki67 proliferation index and stromal CD10 expres-
ion.
In general, unicystic ameloblastoma has a lower recurrence rate
13 to 30%) than polycystic ameloblastoma (50 to 90%) [20] and the
ollicular variant has a higher tendency to local recurrence than
he other architectural variants [21]. In our series, 44% of recur-
ent tumours had a follicular architecture, but with no signiﬁcant
ifference between the various groups (P = 0.087).
Ki67 is used to determine the degree of proliferation of
any tumours, including ameloblastoma and other odontogenic
umours. Evaluation of the proliferation index is an important com-
lementary test to histology in ameloblastoma, and may  possibly
onstitute a marker of biological behaviour, local invasiveness and
umour recurrence [17]. In a series of 14 ameloblastomas, Flo-
escu et al. demonstrated a signiﬁcant difference of Ki67 expression
etween central cells and peripheral cells, considered to be zones
f proliferation [22]. In our study, the Ki67 proliferation index
anged between 2 and 22% with a mean of 10.5%, i.e. comparable
o that observed in the majority of published series, reporting rates
etween 1.6 and 19.8% with a mean of 8.2% [23]. We  observed that
he cell proliferation activity evaluated by Ki67 was signiﬁcantly
igher in recurrent tumours (P = 0.000), thereby suggesting that
i67 can be considered to be a predictive marker of ameloblastoma
nvasiveness and recurrence.
CD10 is an endopeptidase with zinc-dependent metallo-
roteinase enzymatic activity [8]. Stromal CD10 expression is
ssociated with tumour cell differentiation and proliferation. Some
tudies have demonstrated a signiﬁcant correlation between CD10
xpression and tumour progression and metastatic dissemination
or certain types of cancer, especially breast cancer, colorectal can-
er and malignant melanoma [8].
Only a few studies have evaluated CD10 expression in
meloblastoma, with discordant results [17,24]. Recent stud-
es have reported intense stromal CD10 expression in recurrent
meloblastomas [17,24]. These data show that CD10 expression by
tromal cells is associated with tumour invasion of the extracellular
atrix and that proliferation of stromal cells expressing CD10 may
e part of the mechanism of the invasive proﬁle of ameloblastoma
17,24].
The results of the present study support those of the litera-
ure showing a signiﬁcant correlation between CD10 expression
[gy, Head and Neck diseases 132 (2015) 275–279
and recurrence rate (P = 0.002). These results suggest that CD10
can be considered to be a marker of ameloblastoma invasive-
ness and recurrence and consequently a prognostic marker. The
ameloblastoma recurrence rate also varies as a function of treat-
ment modalities, with a recurrence rate between 50 and 87% after
conservative surgery and between 0 and 50% after radical surgery
[20]. In our series, 89% of patients developed recurrence after con-
servative surgery versus 11% after radical surgery, but with no
signiﬁcant difference between the two  groups (P = 0.677).
9. Conclusion
This series, in line with the various series published in the litera-
ture, showed that the Ki67 proliferation index and CD10 expression
by stromal cells appear to be signiﬁcant markers of local invasive-
ness and recurrence of ameloblastoma and therefore constitute
prognostic factors. When these markers are positive, rigorous and
regular postoperative surveillance is required and radical surgery
may  be indicated in the case of recurrence. Other studies, based on
larger series, are necessary to more precisely characterize the role
of Ki67 and CD10 in ameloblastoma tumourigenesis and to develop
new approaches to treatment.
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